Mining comorbidities of opioid use disorder from FDA adverse event reporting system and patient electronic health records
Open accessThe DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.
Abstract
Background: Opioid use disorder (OUD) has become an urgent health problem. People with OUD often experience comorbid medical conditions. Systematical approaches to identifying co-occurring conditions of OUD can facilitate a deeper understanding of OUD mechanisms and drug discovery. This study presents an integrated approach combining data mining, network construction and ranking, and hypothesis-driven case–control studies using patient electronic health records (EHRs). Methods: First, we mined comorbidities from the US Food and Drug Administration Adverse Event Reporting System (FAERS) of 12 million unique case reports using frequent pattern-growth algorithm. The performance of OUD comorbidity mining was measured by precision and recall using manually curated known OUD comorbidities. We then constructed a disease comorbidity network using mined association rules and further prioritized OUD comorbidities. Last, novel OUD comorbidities were independently tested using EHRs of 75 million unique patients. Results: The OUD comorbidities from association rules mining achieves a precision of 38.7% and a recall of 78.2 Based on the mined rules, the global DCN was constructed with 1916 nodes and 32,175 edges. The network-based OUD ranking result shows that 43 of 55 known OUD comorbidities were in the first decile with a precision of 78.2%. Hypothyroidism and type 2 diabetes were two top-ranked novel OUD comorbidities identified by data mining and network ranking algorithms. Based on EHR-based case–control studies, we showed that patients with OUD had significantly increased risk for hyperthyroidism (AOR = 1.46, 95% CI 1.43–1.49, p value < 0.001), hypothyroidism (AOR = 1.45, 95% CI 1.42–1.48, p value < 0.001), type 2-diabetes (AOR = 1.28, 95% CI 1.26–1.29, p value < 0.001), compared with individuals without OUD. Conclusion: Our study developed an integrated approach for identifying and validating novel OUD comorbidities from health records of 87 million unique patients (12 million for discovery and 75 million for validation), which can offer new opportunities for OUD mechanism understanding, drug discovery, and multi-component service delivery for co-occurring medical conditions among patients with OUD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A data mining study from the US Food and Drug Administration Adverse Event Reporting System demonstrated that in patients with OUD, there was positive association with hyperthyroidism (adjusted odds ratio, 1.46; 95% CI, 1.43-1.49)and hypothyroidism (adjusted odds ratio, 1.45; 95% CI, 1.42-1.48)(162).”
From Exogenous Opioids and the Human Endocrine System: An Endocrine Society Scientific Statement (2024) · cites this paper as [162]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A data mining study from the US Food and Drug Administration Adverse Event Reporting System demonstrated that in patients with OUD, there was positive association with hyperthyroidism (adjusted odds ratio, 1.46; 95% CI, 1.43-1.49)and hypothyroidism (adjusted odds ratio, 1.45; 95% CI, 1.42-1.48)(162).”
From Exogenous Opioids and the Human Endocrine System: An Endocrine Society Scientific Statement (2024) · cites this paper as [162]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Variable results have also been described for the peripheral thyroid hormones; T4 levels were unaffected (74, 118, 136, 159, 160) or decreased (116, 160-162) and T3 levels were increased (74, 159) or unaffected (160) or decreased (161).”
From Exogenous Opioids and the Human Endocrine System: An Endocrine Society Scientific Statement (2024) · cites this paper as [162]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Opioid Complications and Side Effects
Benyamin, R. (2008) · Pain Physician · doi:10.36076/ppj.2008/11/s105 · Cited by 2,245
Wang, Q. Q., Kaelber, D. C., Xu, R., & Volkow, N. D. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-00880-7 · Cited by 634
Self-citationWang, Q., Xu, R., & Volkow, N. D. (2021) · World Psychiatry · doi:10.1002/wps.20806 · Cited by 617
Self-citationThe Link between Thyroid Function and Depression
Hage, M. P., & Azar, S. T. (2012) · Journal of Thyroid Research · doi:10.1155/2012/590648 · Cited by 549 · cited 1×
“The association between hypothyroidism and depression has been discussed for years [36], and recent study shows that there is a moderate association of hypothyroidism with clinical depression [37].”
BackgroundCo-occurring substance use and mental disorders among adults with opioid use disorder
Jones, C. M., & McCance-Katz, E. F. (2019) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2018.12.030 · Cited by 464
Normalized names for clinical drugs: RxNorm at 6 years
Nelson, S. J., Zeng, K., Kilbourne, J., Powell, T., & Moore, R. (2011) · Journal of the American Medical Informatics Association · doi:10.1136/amiajnl-2011-000116 · Cited by 453
Management of opioid use disorder in the USA: present status and future directions
Blanco, C., & Volkow, N. D. (2019) · The Lancet · doi:10.1016/s0140-6736(18)33078-2 · Cited by 407
Wang, Q., Berger, N. A., & Xu, R. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2020.6178 · Cited by 390
Self-citationWang, Q., Davis, P. B., Gurney, M. E., & Xu, R. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12296 · Cited by 257
Self-citationA curated and standardized adverse drug event resource to accelerate drug safety research
Banda, J. M., Evans, L., Vanguri, R. S., Tatonetti, N. P., Ryan, P. B., & Shah, N. H. (2016) · Scientific Data · doi:10.1038/sdata.2016.26 · Cited by 246 · cited 1×
“The redundant records were de-duplicated from 14,526,397 to 12,194,096 by only keeping the latest demographics record for each case [20].”
Background
Cited by
Machine Learning-Based Identifications of COVID-19 Fake News Using Biomedical Information Extraction
Fifita, F., Smith, J. J., Hanzsek-Brill, M. B., Li, X., & Zhou, M. (2023) · Big Data and Cognitive Computing · doi:10.3390/bdcc7010046 · Cited by 17
Exogenous Opioids and the Human Endocrine System: An Endocrine Society Scientific Statement
Karavitaki, N., Bettinger, J. J., Biermasz, N., Christ-Crain, M., Gadelha, M. R., Inder, W. J., Tsourdi, E., Wakeman, S. E., & Zatelli, M. (2024) · Endocrine Reviews · doi:10.1210/endrev/bnae023 · Cited by 14
Wen, X., Cai, L., Gao, A., Fu, A., Guo, D., & Zhu, M. (2025) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-025-01867-6 · Cited by 11
Besaw, R. J., & Fry, C. E. (2024) · Health Affairs Scholar · doi:10.1093/haschl/qxae165 · Cited by 9
Li, K., Shuping, S., Chang, S., Yiyue, C., Qinyu, X., Zhang, T., & Wu, B. (2023) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.2389 · Cited by 5
Metadata
- Authors
- Pan, Y., & Xu, R.
- Affiliations
- Case Western Reserve University (US)
- Corresponding author
- Xu, Rong
- ORCID
- Venue
- BMC Medical Informatics and Decision Making
- Published
- 2022-06-16
- Volume
- 22
- Issue
- S2
- Pages
- 155-155
- ISSN
- 1472-6947 (ISSN-L)
- PMC
- PMC9202493
- OpenAlex
- W4283022475
- Semantic Scholar
- fa482bd9fdefc7488a2c6d3958862b9d1d6286b7
- Cited by
- 11
- References
- 29
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 3 · 2023: 3
- FWCI
- 1.76
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- BMC Medical Informatics and Decision Making (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- National Institute on Aging (R01 AG057557, R01 AG061388, R56 AG062272)
- National Institute on Drug Abuse (CTN-0114, UG1DA049435)
- Clinical and Translational Science Collaborative of Cleveland, School of Medicine, Case Western Reserve University (1UL1TR002548-01)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
- Keywords
- opioid use disorder, comorbidities, adverse drug reactions, FDA Adverse Event Reporting System, electronic health records, association rule mining, network ranking, hypothyroidism, hyperthyroidism, type 2 diabetes, frequent pattern mining, drug discovery targets, drug repurposing
- MeSH terms
- Diabetes Mellitus, Type 2, Humans, Hypothyroidism, Opioid-Related Disorders, United States, United States Food and Drug Administration, Comorbidity, Electronic Health Records
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mining comorbidities of opioid use disorder from FDA adverse event reporting system and patient electronic health records. https://app.cochat.ai/papers/10.1186/s12911-022-01869-8
- The paper
- Pan, Y., & Xu, R. (2022). Mining comorbidities of opioid use disorder from FDA adverse event reporting system and patient electronic health records. BMC Medical Informatics and Decision Making. https://doi.org/10.1186/s12911-022-01869-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.